Product Quick Detail

Ziihera® (Zanidatamab-hrii): Prescription biologic targeting IL-23 for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available as 150mg/mL prefilled syringe/pen for subcutaneous injection, and 600mg/10mL vials for IV infusion. Dosage varies based on condition. Refrigerate; protect from light.

Minimum Order: 1

Packaging: N/A

Delivery: 15 Days

Active Ingredient:Risankizumab-rzaa (humanized IgG1 monoclonal antibody targeting interleukin-23 / IL-23p19 subunit)

Strengths/Forms Available:

150 mg/mL solution in single-dose prefilled syringe or pen (for subcutaneous use)
180 mg/mL or other formulations in some regions
600 mg/10 mL (60 mg/mL) in single-dose vial (for intravenous infusion in certain indications)

Indications (approved uses):Moderate to severe plaque psoriasis in adults (candidates for systemic therapy or phototherapy); active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis.

Administration:Subcutaneous injection (most common) or intravenous induction for some indications.

Dosage Examples:

Psoriasis/PsA: 150 mg at Week 0, Week 4, then every 12 weeks.
Crohn's/UC: Induction with IV, then maintenance SC.

Packaging:Single-dose prefilled syringes/pens or vials.

Storage:Refrigerate at 2–8°C (36–46°F); protect from light; do not freeze or shake.

Manufacturer:AbbVie

Other Details:Prescription-only biologic; produced via recombinant DNA in Chinese Hamster Ovary cells; clear to slightly opalescent, colorless to slightly yellow solution.